Neuravi

Neuravi, founded in 2009, has developed an innovative stroke treatment that significantly enhances patient outcomes by preserving abilities and saving lives.

The company’s flagship device, the EmboTrap, is specifically designed to efficiently remove clots from the brain—the primary cause of strokes—thereby facilitating recovery. In 2017 and just two years after receiving its initial investment by EQT Life Sciences, Neuravi was acquired by Johnson & Johnson. Today, EmboTrap devices are widely used to treat patients in both Europe and the United States.